Amgen Urges Full Fed. Circ. Hearing On Repatha Patents
Drugmaker Amgen asked the Federal Circuit on Wednesday for an en banc rehearing of a decision that revived a challenge to its patents for Repatha, an antibody-based cholesterol treatment, saying a...To view the full article, register now.
Already a subscriber? Click here to view full article